207 related articles for article (PubMed ID: 11697742)
1. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.
Gaedigk A; Casley WL; Tyndale RF; Sellers EM; Jurima-Romet M; Leeder JS
Can J Physiol Pharmacol; 2001 Oct; 79(10):841-7. PubMed ID: 11697742
[TBL] [Abstract][Full Text] [Related]
2. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
Br J Clin Pharmacol; 2001 Oct; 52(4):447-50. PubMed ID: 11678789
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
Lee CR; Goldstein JA; Pieper JA
Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
[TBL] [Abstract][Full Text] [Related]
5. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
6. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
[TBL] [Abstract][Full Text] [Related]
7. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
[TBL] [Abstract][Full Text] [Related]
8. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
[TBL] [Abstract][Full Text] [Related]
9. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
[TBL] [Abstract][Full Text] [Related]
10. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
[TBL] [Abstract][Full Text] [Related]
11. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies.
Nowak MP; Sellers EM; Tyndale RF
Clin Pharmacol Ther; 1998 Oct; 64(4):378-83. PubMed ID: 9797794
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.
Leung AY; Chow HC; Kwong YL; Lie AK; Fung AT; Chow WH; Yip AS; Liang R
Blood; 2001 Oct; 98(8):2584-7. PubMed ID: 11588061
[TBL] [Abstract][Full Text] [Related]
13. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations.
Gaedigk A; Tyndale RF; Jurima-Romet M; Sellers EM; Grant DM; Leeder JS
Pharmacogenetics; 1998 Aug; 8(4):305-13. PubMed ID: 9731717
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
[TBL] [Abstract][Full Text] [Related]
15. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol.
Hermida J; Zarza J; Alberca I; Montes R; López ML; Molina E; Rocha E
Blood; 2002 Jun; 99(11):4237-9. PubMed ID: 12010835
[TBL] [Abstract][Full Text] [Related]
17. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
[No Abstract] [Full Text] [Related]
18. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of the human cytochrome P450 CYP2C9 locus.
Stubbins MJ; Harries LW; Smith G; Tarbit MH; Wolf CR
Pharmacogenetics; 1996 Oct; 6(5):429-39. PubMed ID: 8946475
[TBL] [Abstract][Full Text] [Related]
20. Allelic and functional variability of cytochrome P4502C9.
Bhasker CR; Miners JO; Coulter S; Birkett DJ
Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
